Vaccines.
Periodical
Vaccines
Publisher:
MDPI AG
Frequency: Quarterly
Country: Switzerland
Language: English
Author(s):
Multidisciplinary Digital Publishing Institute.
Start Year:2012 -
ISSN:
2076-393X (Electronic)
2076-393X (Linking)
2076-393X (Linking)
Impact Factor
7.8
2022
| NLM ID: | 101629355 |
| (OCoLC): | 852743569 |
| Coden: | VBSABP |
| LCCN: | 2014243731 |
Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.
Vaccines
May 27, 2014
Volume 2, Issue 2 397-421 doi: 10.3390/vaccines2020397
Schwartz EJ, Smith RJ.The ability to predict the conditions under which antibodies protect against viral infection would transform our approach to vaccine development. A more complete understanding is needed of antibody protection against lentivirus infection, as well as the role of mutation in resistance to an antibody vaccine. Recently, an example of antibody-mediated vaccine protection has been shown via passive transfer of neutralizing antibodies before equine infectious anemia virus (EIAV) infection of horses with severe combined immunodeficiency (SCID). Viral dynamic modeling of antibody protection from EIAV ... A Systematic Review of Recent Advances in Equine Influenza Vaccination.
Vaccines
November 14, 2014
Volume 2, Issue 4 797-831 doi: 10.3390/vaccines2040797
Paillot R.Equine influenza (EI) is a major respiratory disease of horses, which is still causing substantial outbreaks worldwide despite several decades of surveillance and prevention. Alongside quarantine procedures, vaccination is widely used to prevent or limit spread of the disease. The panel of EI vaccines commercially available is probably one of the most varied, including whole inactivated virus vaccines, Immuno-Stimulating Complex adjuvanted vaccines (ISCOM and ISCOM-Matrix), a live attenuated equine influenza virus (EIV) vaccine and a recombinant poxvirus-vectored vaccine. Several other strateg... Read More
35
History and Perspective of Immunotherapy for Pythiosis.
Vaccines
September 26, 2021
Volume 9, Issue 10 1080 doi: 10.3390/vaccines9101080
Yolanda H, Krajaejun T.The fungus-like microorganism causes pythiosis, a life-threatening infectious disease increasingly reported worldwide. Antimicrobial drugs are ineffective. Radical surgery is an essential treatment. Pythiosis can resume post-surgically. Immunotherapy using antigens (PIA) has emerged as an alternative treatment. This review aims at providing up-to-date information of the immunotherapeutic PIA, with the focus on its history, preparation, clinical application, outcome, mechanism, and recent advances, in order to promote the proper use and future development of this treatment modality. crude ex... Read More
17
Success and Limitation of Equine Influenza Vaccination: The First Incursion in a Decade of a Florida Clade 1 Equine Influenza Virus that Shakes Protection Despite High Vaccine Coverage.
Vaccines
November 2, 2019
Volume 7, Issue 4 174 doi: 10.3390/vaccines7040174
Fougerolle S, Fortier C, Legrand L, Jourdan M, Marcillaud-Pitel C, Pronost S, Paillot R.Every year, several epizooties of equine influenza (EI) are reported worldwide. However, no EI case has been identified in France between 2015 and late 2018, despite an effective field surveillance of the pathogen and the disease. Vaccination against equine influenza virus (EIV) remains to this day one of the most effective methods to prevent or limit EI outbreaks and the lack of detection of the pathogen could be linked to vaccination coverage. The aim of this study was to evaluate EI immunity and vaccine coverage in France through a large-scale serological study. A total of 3004 archived sur... Read More
14
Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses.
Vaccines
May 9, 2020
Volume 8, Issue 2 213 doi: 10.3390/vaccines8020213
Jonsdottir S, Fettelschoss V, Olomski F, Talker SC, Mirkovitch J, Rhiner T, Birkmann K, Thoms F, Wagner B, Bachmann MF, Kündig TM, Marti E....： Insect bite hypersensitivity (IBH) is an eosinophilic allergic dermatitis of horses caused by type I/IVb reactions against mainly bites. The vaccination of IBH-affected horses with equine IL-5 coupled to the Cucumber mosaic virus-like particle (eIL-5-CuMV) induces IL-5-specific auto-antibodies, resulting in a significant reduction in eosinophil levels in blood and clinical signs. the preclinical and clinical safety of the eIL-5-CuMV vaccine. The B cell responses were assessed by longitudinal measurement of IL-5- and CuMV-specific IgG in the serum and plasma of vaccinated and unvaccinate... Read More
12
Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.
Vaccines
July 14, 2022
Volume 10, Issue 7 doi: 10.3390/vaccines10071124
Jiménez-Cabello L, Utrilla-Trigo S, Barreiro-Piñeiro N, Pose-Boirazian T, Martínez-Costas J, Marín-López A, Ortego J.Bluetongue virus (BTV) and African horse sickness virus (AHSV) are widespread arboviruses that cause important economic losses in the livestock and equine industries, respectively. In addition to these, another arthropod-transmitted orbivirus known as epizootic hemorrhagic disease virus (EHDV) entails a major threat as there is a conducive landscape that nurtures its emergence in non-endemic countries. To date, only vaccinations with live attenuated or inactivated vaccines permit the control of these three viral diseases, although important drawbacks, e.g., low safety profile and effectiveness... Read More
11
Sero-Monitoring of Horses Demonstrates the Equivac® HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres.
Vaccines
July 2, 2021
Volume 9, Issue 7 731 doi: 10.3390/vaccines9070731
Halpin K, Graham K, Durr PA.Hendra virus (HeV) is a high consequence zoonotic pathogen found in Australia. The HeV vaccine was developed for use in horses and provides a One Health solution to the prevention of human disease. By protecting horses from infection, the vaccine indirectly protects humans as well, as horses are the only known source of infection for humans. The sub-unit-based vaccine, containing recombinant HeV soluble G (sG) glycoprotein, was released by Pfizer Animal Health (now Zoetis) for use in Australia at the end of 2012. The purpose of this study was to collate post-vaccination serum neutralising anti... Read More
10
Equine Vaccines: How, When and Why? Report of the Vaccinology Session, French Equine Veterinarians Association, 2016, Reims.
Vaccines
December 4, 2017
Volume 5, Issue 4 46 doi: 10.3390/vaccines5040046
Paillot R, Marcillaud Pitel C, D'Ablon X, Pronost S.To date, vaccination is one of the most efficient methods of prevention against equine infectious diseases. The vaccinology session, which was organised during the annual meeting of the French Equine Veterinarians Association (AVEF) at Reims (France) in 2016, aimed to approach three subjects of importance for the equine industry. Vaccination against three major equine diseases were used as examples: equine influenza (equine influenza virus), rhinopneumonitis (equine herpes virus 1/4), and tetanus ( neuro-toxin). (1) Emergency vaccination: while it has been very successful to reduce the impact ... Read More
10
Determining Equine Influenza Virus Vaccine Efficacy-The Specific Contribution of Strain Versus Other Vaccine Attributes.
Vaccines
September 3, 2020
Volume 8, Issue 3 501 doi: 10.3390/vaccines8030501
Reemers S, Sonnemans D, Horspool L, van Bommel S, Cao Q, van de Zande S.Vaccination is an effective tool to limit equine influenza virus (EIV H3N8) infection, a contagious respiratory disease with potentially huge economic impact. The study assessed the effects of antigenic change on vaccine efficacy and the need for strain update. Horses were vaccinated (V1 and V2) with an ISCOMatrix-adjuvanted, whole inactivated virus vaccine (Equilis Prequenza, group 2, FC1 and European strains) or a carbomer-adjuvanted, modified vector vaccine (ProteqFlu, group 3, FC1 and FC2 HA genes). Serology (SRH, HI, VN), clinical signs and viral shedding were assessed in comparison to un... Response of Sport Horses to Different Formulations of Equine Influenza Vaccine.
Vaccines
July 10, 2020
Volume 8, Issue 3 doi: 10.3390/vaccines8030372
Entenfellner J, Gahan J, Garvey M, Walsh C, Venner M, Cullinane A.The international governing body of equestrian sports requires that horses be vaccinated against equine influenza within 6 months and 21 days of competing. The aim of this study was to compare the antibody response of young sport horses to six-monthly booster vaccination with equine influenza vaccines of different formulations. An inactivated vaccine was allocated to 35 horses and subunit and recombinant vaccines were allocated to 34 horses each. After vaccination, all horses were monitored for evidence of adverse reactions. Whole blood samples were collected at the time of vaccination and on ... The Immunity Gap Challenge: Protection against a Recent Florida Clade 2 Equine Influenza Strain.
Vaccines
July 2, 2018
Volume 6, Issue 3 38 doi: 10.3390/vaccines6030038
Paillot R, Garrett D, Lopez-Alvarez MR, Birand I, Montesso F, Horspool L.Vaccination is one of the most effective tools for limiting the impact of equine influenza (EI). The humoral immunity established following a primary vaccination course can decrease significantly between the second (V2) and third immunisations (V3), leaving some horses insufficiently protected for several weeks. This so-called "immunity gap" poses a challenge to all EI vaccines. During this period, the EI infection of vaccinated animals may be followed by marked clinical signs and virus shedding. However, several EI vaccines have been shown to stimulate equine influenza virus (EIV)-specific ce... Evaluation of Current Equine Influenza Vaccination Protocols Prior to Shipment, Guided by OIE Standards.
Vaccines
February 29, 2020
Volume 8, Issue 1 107 doi: 10.3390/vaccines8010107
Cullinane A, Gahan J, Walsh C, Nemoto M, Entenfellner J, Olguin-Perglione C, Garvey M, Huang Fu TQ, Venner M, Yamanaka T, Barrandeguy M, Fernandez CJ.To facilitate the temporary importation of horses for competition and racing purposes, with a minimum risk of transmitting equine influenza, the World Organisation for Animal Health (Office International des Epizooties, or OIE), formally engaged in a public-private partnership with the Federation Equestre Internationale (FEI) and the International Federation for Horseracing Authorities (IFHA) to establish, within the context of existing OIE standards, a science-based rationale to identify the ideal time period for equine influenza vaccination prior to shipment. Field trials using vaccines base... Equine PBMC Cytokines Profile after In Vitro α- and γ-EHV Infection: Efficacy of a Parapoxvirus Ovis Based-Immunomodulator Treatment.
Vaccines
September 19, 2017
Volume 5, Issue 3 28 doi: 10.3390/vaccines5030028
Hue ES, Richard EA, Fortier CI, Fortier GD, Paillot R, Raue R, Pronost SL.Equine herpesviruses (EHV) infect horses early during life and the persistence of these viruses through establishment of latency represents a real risk. A better understanding of the immune response to EHV infection is necessary to improve our methods of prevention and decrease the risk of transmission. The objectives of this study were to characterise the cytokine gene expression profile of peripheral blood mononuclear cells (PBMC) after in vitro EHV-1, EHV-4, and EHV-2 infection and to determine the efficacy of inactivated (iPPVO) against these 3 viruses. PBMC were isolated from 3 horses an... Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines.
Vaccines
March 30, 2023
Volume 11, Issue 4 769 doi: 10.3390/vaccines11040769
Jindra C, Hainisch EK, Brandt S.Horses and other equid species are frequently affected by bovine papillomavirus type 1 and/or 2 (BPV1, BPV2)-induced skin tumors termed sarcoids. Although sarcoids do not metastasize, they constitute a serious health problem due to their BPV1/2-mediated resistance to treatment and propensity to recrudesce in a more severe, multiple form following accidental or iatrogenic trauma. This review provides an overview on BPV1/2 infection and associated immune escape in the equid host and presents early and recent immunotherapeutic approaches in sarcoid management. Equids’ Core Vaccines Guidelines in North America: Considerations and Prospective.
Vaccines
March 4, 2022
Volume 10, Issue 3 doi: 10.3390/vaccines10030398
Desanti-Consoli H, Bouillon J, Chapuis RJJ.Vaccination against infectious diseases is a cornerstone of veterinary medicine in the prevention of disease transmission, illness severity, and often death in animals. In North American equine medicine, equine vaccines protecting against tetanus, rabies, Eastern and Western equine encephalomyelitis, and West Nile are core vaccines as these have been classified as having a heightened risk of mortality, infectiousness, and endemic status. Some guidelines differ from the label of vaccines, to improve the protection of patients or to decrease the unnecessary administration to reduce potential sid... Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study.
Vaccines
February 17, 2021
Volume 9, Issue 2 166 doi: 10.3390/vaccines9020166
Pavulraj S, Bergmann T, Trombetta CM, Marchi S, Montomoli E, Alami SSE, Ragni-Alunni R, Osterrieder N, Azab W.Equine influenza (EI) is a highly contagious acute respiratory disease of equines that is caused mainly by the H3N8 subtype of influenza A virus. Vaccinating horses against EI is the most effective strategy to prevent the infection. The current study aimed to compare the kinetics of EI-specific humoral- and cell-mediated immunity (CMI) in horses receiving either identical or mixed vaccinations. Two groups of horses were previously (six months prior) vaccinated with either Calvenza 03 EIV EHV (G1) or Fluvac Innovator (G2) vaccine. Subsequently, both groups received a booster single dose of Calv... Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses.
Vaccines
October 4, 2018
Volume 6, Issue 4 71 doi: 10.3390/vaccines6040071
Dilai M, Piro M, El Harrak M, Fougerolle S, Dehhaoui M, Dikrallah A, Legrand L, Paillot R, Fassi Fihri O.To evaluate the humoral immune response to mixed Equine Influenza vaccination, a common practice in the field, an experimental study was carried out on 42 unvaccinated thoroughbred weanling foals divided into six groups of seven. Three groups were vaccinated using a non-mixed protocol (Equilis Prequenza-Te, Proteqflu-Te or Calvenza-03) and three other groups were vaccinated using a mix of the three vaccines mentioned previously. Each weanling underwent a primary EI vaccination schedule composed of two primary immunisations (V1 and V2) four weeks apart followed by a third boost immunisation (V3... Rationally Attenuated Vaccines for Venezuelan Equine Encephalitis Protect Against Epidemic Strains with a Single Dose.
Vaccines
September 2, 2020
Volume 8, Issue 3 497 doi: 10.3390/vaccines8030497
Rossi SL, Russell-Lodrigue KE, Plante KS, Bergren NA, Gorchakov R, Roy CJ, Weaver SC.Venezuelan equine encephalitis virus (VEEV) is a re-emerging virus of human, agriculture, and bioweapon threat importance. No FDA-approved treatment is available to combat Venezuelan equine encephalitis in humans, prompting the need to create a vaccine that is safe, efficacious, and cannot be replicated in the mosquito vector. Here we describe the use of a serotype ID VEEV (ZPC-738) vaccine with an internal ribosome entry site (IRES) to alter gene expression patterns. This ZPC/IRES vaccine was genetically engineered in two ways based on the position of the IRES insertion to create a vaccine th... Evaluation of Three Different Vaccination Protocols against EHV1/EHV4 Infection in Mares: Double Blind, Randomized Clinical Trial.
Vaccines
June 1, 2020
Volume 8, Issue 2 268 doi: 10.3390/vaccines8020268
EHV1 and EHV4 are the most important herpesviruses in horses. Repeated cases of abortion in mares regularly vaccinated, prompted us to investigate the immune response after vaccination with the same inactivated vaccine, but with three different protocols. Eighteen mares were chosen and randomly divided in three study groups (G-G-G) and a control group (Ctrl). For serologic and PCR investigations nasal swabs, sera and blood were collected. The protocol used in G (4 doses) increased the titer recorded by ELISA and seroneutralization (SN). Poor agreement and no correlation were observed in titer ... Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.
Vaccines
May 27, 2014
Volume 2, Issue 2 397-421 doi: 10.3390/vaccines2020397
Schwartz EJ, Smith RJ.The ability to predict the conditions under which antibodies protect against viral infection would transform our approach to vaccine development. A more complete understanding is needed of antibody protection against lentivirus infection, as well as the role of mutation in resistance to an antibody vaccine. Recently, an example of antibody-mediated vaccine protection has been shown via passive transfer of neutralizing antibodies before equine infectious anemia virus (EIAV) infection of horses with severe combined immunodeficiency (SCID). Viral dynamic modeling of antibody protection from EIAV ... Evaluation of a Pseudotyped Virus Neutralisation Test for the Measurement of Equine Influenza Virus-Neutralising Antibody Responses Induced by Vaccination and Infection.
Vaccines
August 21, 2020
Volume 8, Issue 3 466 doi: 10.3390/vaccines8030466
Kinsley R, Pronost S, De Bock M, Temperton N, Daly JM, Paillot R, Scott S.Equine influenza is a major respiratory disease of horses that is largely controlled by vaccination in some equine populations. Virus-neutralising antibodies, the mainstay of the protective immune response, are problematic in assaying for equine influenza virus, as most strains do not replicate efficiently in cell culture. Surrogate measures of protective antibody responses include the haemagglutination inhibition (HI) test and single radial haemolysis (SRH) assay. For this study, a pseudotyped virus, bearing an envelope containing the haemagglutinin (HA) from the Florida clade 2 equine influe... Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin.
Vaccines
September 14, 2022
Volume 10, Issue 9 1522 doi: 10.3390/vaccines10091522
Ben David A, Barnea A, Torgeman A, Diamant E, Dor E, Schwartz A, Rosen O, Caspi N, Saraf M, Lerer E, Adar Y, Lupo E, Toister E, Zichel R.Botulism is a paralytic disease caused by botulinum neurotoxins (BoNTs). Equine antitoxin is currently the standard therapy for botulism in human. The preparation of equine antitoxin relies on the immunization of horses with botulinum toxoid, which suffers from low yield and safety limitations. The Hc fragment of BoNTs was suggested to be a potent antibotulinum subunit vaccine. The current study presents a comparative evaluation of equine-based toxoid-derived antitoxin (TDA) and subunit-derived antitoxin (SDA). The potency of recombinant Hc/A, Hc/B, and Hc/E in mice was similar to that of toxo... An Outbreak of Equine Herpesvirus-4 in an Ecological Donkey Milk Farm in Romania.
Vaccines
March 18, 2022
Volume 10, Issue 3 468 doi: 10.3390/vaccines10030468
Mureşan A, Mureşan C, Siteavu M, Avram E, Bochynska D, Taulescu M.Equine herpesviruses are important pathogens causing significant economic loss in equine and asinine populations. EHV-1/4 strains are mainly associated with respiratory distress. The aim of this study is to report the first EHV 4-associated respiratory disease in donkeys in Romania. Thirty-seven of three hundred jennies in an ecological donkey farm in southwest Romania started initially showing signs of severe upper respiratory tract disease, with ten concomitant late abortions/neonatal deaths and three neurological cases. There were nine fatalities. Pathological examination was performed, and... Immunostimulating Effect of Inactivated Parapoxvirus Ovis on the Serological Response to Equine Influenza Booster Vaccination.
Vaccines
December 14, 2022
Volume 10, Issue 12 2139 doi: 10.3390/vaccines10122139
Carnet F, Paillot R, Fortier C, Hue ES, Briot L, de Geoffroy F, Vidalain PO, Pronost S.Equine influenza virus (EIV) is responsible for recurring outbreaks that are detrimental to the equine industry. Vaccination is key for prevention, but the effectiveness and duration of protection provided by existing vaccines is often insufficient. In order to improve vaccine efficacy, we evaluated the benefit of immune stimulation with inactivated Parapoxvirus ovis (iPPVO) on the antibody response induced by a vaccine boost against EIV. A whole inactivated ISCOMatrix-adjuvanted equine influenza vaccine was administered alone ( = 10) or combined with iPPVO injections at D0, D2 and D4 post vac... Communication Interventions and Assessment of Drivers for Hendra Virus Vaccination Uptake.
Vaccines
May 4, 2023
Volume 11, Issue 5 doi: 10.3390/vaccines11050936
Kropich-Grant JN, Wiley KE, Manyweathers J, Thompson KR, Brookes VJ.Hendra virus disease (HeVD) is an emerging zoonosis in Australia, resulting from the transmission of Hendra virus (HeV) to horses from Pteropus bats. Vaccine uptake for horses is low despite the high case fatality rate of HeVD in both horses and people. We reviewed evidence-based communication interventions to promote and improve HeV vaccine uptake for horses by horse owners and conducted a preliminary evaluation of potential drivers for HeV vaccine uptake using the Behavioural and Social Drivers of Vaccination (BeSD) framework developed by the World Health Organization. Six records were eligi... Protection against the New Equine Influenza Virus Florida Clade I Outbreak Strain Provided by a Whole Inactivated Virus Vaccine.
Vaccines
December 21, 2020
Volume 8, Issue 4 784 doi: 10.3390/vaccines8040784
Reemers S, van Bommel S, Cao Q, Sutton D, van de Zande S.Equine influenza virus (EIV) is a major cause of respiratory disease in horses. Vaccination is an effective tool for infection control. Although various EIV vaccines are widely available, major outbreaks occurred in Europe in 2018 involving a new EIV H3N8 FC1 strain. In France, it was reported that both unvaccinated and vaccinated horses were affected despite >80% vaccination coverage and most horses being vaccinated with a vaccine expressing FC1 antigen. This study assessed whether vaccine type, next to antigenic difference between vaccine and field strain, plays a role. Horses were vaccin... Assessment of Humoral and Long-Term Cell-Mediated Immune Responses to Recombinant Canarypox-Vectored Equine Influenza Virus Vaccination in Horses Using Conventional and Accelerated Regimens Respectively.
Vaccines
May 26, 2022
Volume 10, Issue 6 855 doi: 10.3390/vaccines10060855
El-Hage C, Hartley C, Savage C, Watson J, Gilkerson J, Paillot R.During Australia's first and only outbreak of equine influenza (EI), which was restricted to two northeastern states, horses were strategically vaccinated with a recombinant canarypox-vectored vaccine (rCP-EIV; ProteqFlu™, Merial P/L). The vaccine encoded for haemagglutinin (HA) belonging to two equine influenza viruses (EIVs), including an American and Eurasian lineage subtype that predated the EIV responsible for the outbreak (A/equine/Sydney/07). Racehorses in Victoria (a southern state that remained free of EI) were vaccinated prophylactically. Although the vaccine encoded for (HA) belon... Equine Influenza Virus: An Old Known Enemy in the Americas.
Vaccines
October 14, 2022
Volume 10, Issue 10 doi: 10.3390/vaccines10101718
Gonzalez-Obando J, Forero JE, Zuluaga-Cabrera AM, Ruiz-Saenz J.Equine influenza is a highly contagious disease caused by the H3N8 equine influenza virus (EIV), which is endemically distributed throughout the world. It infects equids, and interspecies transmission to dogs has been reported. The H3N8 Florida lineage, which is divided into clades 1 and 2, is the most representative lineage in the Americas. The EIV infects the respiratory system, affecting the ciliated epithelial cells and preventing the elimination of foreign bodies and substances. Certain factors related to the disease, such as an outdated vaccination plan, age, training, and close contact ... Clostridial Diseases of Horses: A Review.
Vaccines
February 17, 2022
Volume 10, Issue 2 doi: 10.3390/vaccines10020318
Uzal FA, Navarro MA, Asin J, Henderson EE.The clostridial diseases of horses can be divided into three major groups: enteric/enterotoxic, histotoxic, and neurotoxic. The main enteric/enterotoxic diseases include those produced by Clostridium perfringens type C and Clostridioides difficile, both of which are characterized by enterocolitis. The main histotoxic diseases are gas gangrene, Tyzzer disease, and infectious necrotic hepatitis. Gas gangrene is produced by one or more of the following microorganisms: C. perfringens type A, Clostridium septicum, Paeniclostridium sordellii, and Clostridium novyi type A, and it is characterized by ... Immunocontraceptive Efficacy of Native Porcine Zona Pellucida (pZP) Treatment of Nevada’s Virginia Range Free-Roaming Horse Population.
Vaccines
January 18, 2024
Volume 12, Issue 1 doi: 10.3390/vaccines12010096
Schulman ML, Hayes NK, Wilson TA, Grewar JD.In North America, range constraints due to burgeoning development increasingly encroach on wild horse habitat and necessitate effective but humane reproductive management. The largest free-roaming wild horse fertility control program by population (>3500) and territory size (≈300,000 acres) is located within Nevada's Virginia Range. Data from a field study investigated porcine zona pellucida (pZP) immunocontraception via remote dart delivery to mares in this population. Analyses aimed to measure efficacy by treatment effects on annual birth rates and population demographics and to evaluate t... Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses.
Vaccines
May 21, 2024
Volume 12, Issue 6 doi: 10.3390/vaccines12060562
Birkmann K, Jebbawi F, Waldern N, Hug S, Inversini V, Keller G, Holm A, Grest P, Canonica F, Schmid-Grendelmeier P, Fettelschoss-Gabriel A.Urticaria, independent of or associated with allergies, is commonly seen in horses and often shows a high reoccurrence rate. Managing these horses is discouraging, and efficient treatment options are lacking. Due to an incidental finding in a study on horses affected by insect bite hypersensitivity using the eosinophil-targeting eIL-5-CuMV-TT vaccine, we observed the prevention of reoccurring seasonal urticaria in four subsequent years with re-vaccination. In an exploratory case series of horses affected with non-seasonal urticaria, we aimed to investigate the role of eosinophils in urticaria....